RecruitingPhase 3NCT06836557

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

Studying Idiopathic gastroparesis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vanda Pharmaceuticals
Principal Investigator
Vanda Pharmaceuticals
Vanda Pharmaceuticals
Intervention
Tradipitant(drug)
Enrollment
100 target
Eligibility
18-70 years · All sexes
Timeline
2024 – 2025

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06836557 on ClinicalTrials.gov

Other trials for Idiopathic gastroparesis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic gastroparesis →

← Back to all trials